Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $9.10 and traded as low as $7.96. Enanta Pharmaceuticals shares last traded at $8.09, with a volume of 377,139 shares trading hands.

Analysts Set New Price Targets

A number of research firms have weighed in on ENTA. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Performance

The stock has a market cap of $172.58 million, a PE ratio of -1.63 and a beta of 0.54. The business has a 50 day moving average price of $5.90 and a two-hundred day moving average price of $9.10.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.89% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently bought and sold shares of ENTA. US Bancorp DE raised its stake in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of Enanta Pharmaceuticals by 65.0% in the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 7,535 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $122,000. Valence8 US LP bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at about $207,000. Finally, FMR LLC lifted its position in Enanta Pharmaceuticals by 18.9% in the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after buying an additional 7,839 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.